In addition, germline genetic testing plays a crucial role in cancer treatment, as BRCA1/2 mutations are predictive of a positive response to PARP inhibitors and platinum-based chemotherapy, while mutations in mismatch repair genes suggest potential benefits from immune checkpoint inhibitors [50]. Here, BRCA1 is linked to cancer.